熱門資訊> 正文
Rocket Pharma更新了RP-A501治疗达农病的进展
2026-10-07 23:44
- Rocket Pharmaceuticals (RCKT) said that it has a clear path to complete a pivotal phase 2 trial for its Danon disease asset, RP-A501.
- The company said 12 male patients will receive treatment. Co-primary endpoints are myocardial LAMP2 protein expression of at least Grade 1 and a reduction in left ventricular mass index of at least 10% from baseline after one year.
- If met, Rocket could seek a potential accelerated approval pathway.
- Phase 1 results showed that at around 12 months, the six patients in the main phase 1 analysis had myocardial LAMP2 protein expression and at least a 10% reduction in left ventricular mass index. At follow-up of three to seven years, left ventricular mass index was below baseline in five of six patients, with reductions of at least 10% in four patients.
- Danon disease is a rare genetic disorder characterized by cardiomyopathy and muscle weakness.
More on Rocket Pharmaceuticals
- Rocket Pharmaceuticals, Inc. (RCKT) Discusses Danon Disease Program Update With Focus on RP-A501 Pivotal Trial and Preliminary Clinical Data Transcript
- Rocket Pharmaceuticals, Inc. (RCKT) Discusses Danon Disease Program Update With Focus on RP-A501 Pivotal Trial and Preliminary Clinical Data - Slideshow
- Rocket Pharmaceuticals, Inc. (RCKT) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
- Rocket Pharma upgraded at Needham as FDA OKs pivotal trial design
- Seeking Alpha’s Quant Rating on Rocket Pharmaceuticals
推薦文章
美股夜盤 | 民主黨選情走強！SpaceX大跌5%！特斯拉跌逾4%；存儲股普跌，SK海力士跌超5%
華盛早報 | 今日揭曉結果！中期選舉或決定市場走向；美芯片股反攻！AMD、超微電腦績后飆升；韓股盤初大漲，SK海力士大漲5%
美債利率逼近 5%：強勁就業數據引爆美元與黃金的劇烈博弈
AMD財報后股價大漲7%，數據中心營收近乎翻倍
中期選舉：若民主黨橫掃國會，股市或將迎來震盪
「反AI交易」火了？可口可樂年漲逾40%，禮來頻創新高！防禦板塊成為資金的下一個風口？
美股前瞻 | 中期選舉投票開啟！或影響美債、通脹與AI；蘋果盤前跌逾4%，毛利率指引遠遜預期；存儲、光通信股盤前反彈，閃迪升逾4%
美股前瞻 | 存儲股集體反攻！野村喊話「定價嚴重誤判」；油價重挫4%，美伊擬尋求外交途徑解決衝突；邁威爾科技1150億美元收購落定
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
